2015 was great for genetic diagnostics but 2016 will be even better

Published on December 18, 2015

As the holiday season is approaching, we want to thank all of our customers, partners and collaborators for the great year. During 2015 we expanded into new territories and had the privilege to learn from and work with physicians and researchers from all over the world. We are very pleased with the improvements we have made to our services, including decreasing our turnaround time average to well below 21 days.

We are even more excited about 2016. So far we have been mainly providing diagnostics for inherited cardiovascular disorders. However, beginning in March we will become a genetic diagnostics one-stop shop by introducing the most comprehensive NGS diagnostics platform in the world. We are launching more than 250 high-quality NGS panels covering practically all actionable inherited disorders from 18 medical specialties. We are also introducing copy number variation (CNV) detection along with mitochondrial sequencing to supplement our mutation testing panels.
In addition, we will start addressing patient cases with complex phenotypes by introducing Medical Exome Sequencing that will cover 1,200 clinically relevant and actionable genes with extremely high clinical-grade sequencing quality. Moreover, based on the feedback from many customers, we will start providing Whole Exome Sequencing for disease gene discovery and analysis of family trios.

The most important part of our service is the clinical statement that we send to our customers. Our mission is to provide best-in-class clinical reports to bring actionable genetic knowledge for physicians and patients worldwide, and this is what we will be striving for in 2016. We are very much looking forward to continuing to work with our exisiting customers and collaborating with new ones.

We wish you a happy holiday season and a great New Year!

Blueprint Genetics Team

Last modified: 12.18.2015

News

Difficult-to-sequence genes in ophthalmology: improved sequencing coverage and mapping quality in ORF15 enable unmatched diagnostic yield in XLRP

Published on April 30, 2018

Blueprint Genetics’ updated technology enables improved coverage and sensitivity in clinically relevant and challenging genes such as RPGR and especially the ORF15 region of this gene. Current next generations sequencing (NGS) strategies and standard Sanger sequencing do not adequately cover the RPGR ORF15 region, leading to poor sensitivity and decreased…

Read more

Subscribe to our newsletter